Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03301636 | A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma(NLG2107) | terminated | Phase 2 | 21 | NewLink Genetics CorporationINDUSTRY | 1 | Sep 27, 2022 | clinicaltrials |
| NCT03259425 | Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma | terminated | Phase 2 | 7 | University of UtahOTHER | 1 | Jun 13, 2022 |
| clinicaltrials |
| NCT02459067 | ImmuniCell® in Patients With Advanced Cancers | terminated | Phase 2 | 8 | TC BiopharmINDUSTRY | 1 | Mar 10, 2022 | clinicaltrials |
| NCT01650350 | Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer | terminated | Phase 2 | 7 | Brown UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT02054104 | Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum | terminated | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2022 | clinicaltrials |
| NCT02009384 | Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox | terminated | Phase 2 | 2 | University of LouisvilleOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT00615160 | PTK/ZK in Disseminated Malignant Melanoma | terminated | Phase 1 / Phase 2 | 9 | Michael WeichenthalOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT02375984 | A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas(TIL) | terminated | Phase 2 | 1 | Saint John's Cancer InstituteOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT02974803 | Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases | terminated | Phase 2 | 6 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 20, 2021 | clinicaltrials |
| NCT02521870 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 241 | Dynavax Technologies CorporationINDUSTRY | 4 | Aug 3, 2021 | clinicaltrials |
| NCT02097732 | Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery | terminated | Phase 2 | 4 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 12, 2021 | clinicaltrials |
| NCT03224208 | Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients(VECODUE) | terminated | Phase 2 | 9 | Fondazione Melanoma OnlusOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT03724968 | Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression | terminated | Phase 2 | 2 | Elizabeth DavisOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT00961844 | Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma | terminated | Phase 1 / Phase 2 | 15 | Steinar AamdalOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT02303951 | Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC(NEO-VC) | terminated | Phase 2 | 47 | University Hospital TuebingenOTHER | 2 | Feb 3, 2021 | clinicaltrials |
| NCT03728465 | Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma | terminated | Phase 2 | 6 | University Hospital TuebingenOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT00515528 | Vaccination Plus Ontak in Patients With Metastatic Melanoma | terminated | Phase 2 | 17 | University of ChicagoOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT00003509 | Antineoplaston Therapy in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 13 | Burzynski Research InstituteOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT03354962 | Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) | terminated | Phase 1 / Phase 2 | 6 | Institut Claudius RegaudOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT03241927 | Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT) | terminated | Phase 2 | 1 | Nina BhardwajOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02410863 | Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma(BOTTOM) | terminated | Phase 2 | 10 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT00706238 | MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma | terminated | Phase 2 | 5 | GlaxoSmithKlineINDUSTRY | 3 | Oct 8, 2020 | clinicaltrials |
| NCT01942993 | The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma | terminated | Phase 2 | 3 | Philip FriedlanderOTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT00505635 | Biochemotherapy With Temozolomide for Metastatic Melanoma | terminated | Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT01801358 | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 38 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 6 | Sep 16, 2020 | clinicaltrials |
| NCT01590082 | Doxycycline, Temozolomide and Ipilimumab in Melanoma | terminated | Phase 1 / Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT02889861 | IMCgp100-401 Rollover Study | terminated | Phase 2 | 3 | Immunocore LtdINDUSTRY | 2 | Jul 27, 2020 | clinicaltrials |
| NCT03407170 | Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) | terminated | Phase 2 | 1 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jul 15, 2020 | clinicaltrials |
| NCT01308294 | Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients(LAG-3/IMP321) | terminated | Phase 1 / Phase 2 | 16 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03580382 | Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma | terminated | Phase 1 / Phase 2 | 3 | NYU Langone HealthOTHER | 1 | May 20, 2020 | clinicaltrials |
| NCT02385669 | A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma(Mel62; 6PAC) | terminated | Phase 1 / Phase 2 | 3 | Craig L Slingluff, JrOTHER | 1 | May 5, 2020 | clinicaltrials |
| NCT02718391 | Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients.(ACDC) | terminated | Phase 2 | 12 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Apr 22, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT01970527 | Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 23 | University of WashingtonOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02587650 | Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | terminated | Phase 2 | 1 | University of California, San FranciscoOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT01437605 | Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC | terminated | Phase 2 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT03300843 | Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01218867 | CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT01369875 | Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT02190838 | Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma | terminated | Phase 2 | 57 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT00670748 | Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | terminated | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2019 | clinicaltrials |
| NCT01264081 | Lapatinib in Stage IV Melanoma With ERBB4 Mutations | terminated | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Nov 13, 2019 | clinicaltrials |
| NCT02359851 | Pembrolizumab in Treating Patients With Advanced Uveal Melanoma | terminated | Phase 2 | 5 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 18, 2019 | clinicaltrials |
| NCT02302339 | A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma | terminated | Phase 2 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Sep 6, 2019 | clinicaltrials |
| NCT01471054 | Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma | terminated | Phase 2 | 6 | Arman MashayekhiOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT00729807 | 0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma | terminated | Phase 2 | 6 | University of Maryland, BaltimoreOTHER | 1 | Aug 16, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Sep 27, 2022source: clinicaltrials